Menu

Blog

Feb 27, 2018

All-star team of synthetic biologists raise $53 million for cancer therapy startup Senti

Posted by in categories: bioengineering, biotech/medical, finance, genetics

A who’s-who from the world of synthetic biological research have come together to launch Senti Biosciences with $53 million in funding from a slew of venture capital investors.

Led by Tim Lu, a longtime researcher at the Massachusetts Institute of Technology and one of the founding fathers of synthetic biology, Senti’s aim is nothing less than developing therapies that are tailored to an individual’s unique biology — and their first target is cancer.

Here’s how Lu described a potential cancer treatment using Senti’s technology to me. “We take a cell derived from humans that we can insert our genetic circuits into… we insert the DNA and encoding and deliver those cells via an IV infusion. We have engineered the cells to locate where the tumors are… What we’ve been doing is engineering those cells to selectively trigger an immune response against the tumor.”

Read more

Comments are closed.